Phase II study of maintenance therapy of OSE-2101 (Tedopi®) combined with immune checkpoint inhibitor or alone versus Folfiri (combination chemotherapy with folinic acid, fluorouracil and irinotecan) in patients with locally advanced or metastatic pancreatic cancer

Trial Profile

Phase II study of maintenance therapy of OSE-2101 (Tedopi®) combined with immune checkpoint inhibitor or alone versus Folfiri (combination chemotherapy with folinic acid, fluorouracil and irinotecan) in patients with locally advanced or metastatic pancreatic cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs OSE 2101 (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Sep 2017 New trial record
    • 06 Sep 2017 According to an OSE Immunotherapeutics media release, the company announced an agreement with GERCOR, to study OSE-2101 in locally advanced or metastatic pancreatic cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top